Gp100:209-217(210M)

From Wikipedia, the free encyclopedia

Gp100:209-217(210M) is a synthetic peptide cancer vaccine consisting of amino acid residues 209 through 217 of the glycoprotein 100 (gp100) melanoma antigen, with a methionine substitution at position 210.[1] It is often referred to as the gp100 cancer vaccine which can also include other peptides based on gp100 (for example gp100:280-288(288V) [2][3]).

Clinical trials

It gave good results in a trial for advanced melanoma when used in combination with interleukin-2.[4]

Another trial against Ipilimumab in advanced melanoma suggested Ipilimumab may be better than the gp100 vaccine alone.[5]

References

  1. ↑ http://www.cancer.gov/drugdictionary/?CdrID=476335
  2. ↑ http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=492712
  3. ↑ "Re-induction with ipilimumab, gp100 peptide vaccine, or a combination of both from a phase III, randomized, double-blind, multicenter study of previously treated patients with unresectable stage III or IV melanoma". 2010. 
  4. ↑ "Vaccine shows promise in advanced melanoma -study". Reuters. 30 may 2009. 
  5. ↑ http://www.genengnews.com/gen-news-highlights/bms-ipilimumab-proves-itself-in-metastatic-melanoma-patients/81243496/


This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.